{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T12:15:20Z","timestamp":1743077720442,"version":"3.40.3"},"publisher-location":"Cham","reference-count":91,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319131498"},{"type":"electronic","value":"9783319131504"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-3-319-13150-4_8","type":"book-chapter","created":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T02:05:53Z","timestamp":1423188353000},"page":"197-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current Therapeutic Strategies and New Treatment Paradigms for Follicular Lymphoma"],"prefix":"10.1007","author":[{"given":"Athena","family":"Kritharis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,7]]},"reference":[{"key":"8_CR1","doi-asserted-by":"crossref","unstructured":"Chan WC, Armitage JO, Gascoyne R et al (1997) A clinical evaluation of the international lymphoma study group classification of non-Hodgkin\u2019s lymphoma. The non-Hodgkin\u2019s lymphoma classification project. Blood 89(11):3909\u20133918","DOI":"10.1182\/blood.V89.11.3909"},{"issue":"1","key":"8_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood 107(1):265\u2013276","journal-title":"Blood"},{"issue":"26","key":"8_CR3","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS et al (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol 31(26):3272\u20133278","journal-title":"J Clin Oncol"},{"issue":"6","key":"8_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT et al (2013) Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 122(6):981\u2013987","journal-title":"Blood"},{"issue":"6","key":"8_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ajh.23708","volume":"89","author":"C Nabhan","year":"2014","unstructured":"Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Kruczek K, Smith SM, Evens AM (2014) The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras. Am J Hematol 89(6):633\u2013638","journal-title":"Am J Hematol"},{"issue":"12","key":"8_CR6","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A et al (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31(12):1506\u20131513","journal-title":"J Clin Oncol"},{"issue":"3","key":"8_CR7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E et al (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 15(3):1110\u20131117","journal-title":"J Clin Oncol"},{"issue":"7","key":"8_CR8","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","volume":"16","author":"P Solal-Celigny","year":"1998","unstructured":"Solal-Celigny P, Lepage E, Brousse N et al (1998) Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d\u2019Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 16(7):2332\u20132338","journal-title":"J Clin Oncol"},{"issue":"4","key":"8_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P et al (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 15(4):424\u2013435","journal-title":"Lancet Oncol"},{"issue":"9383","key":"8_CR10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362(9383):516\u2013522","journal-title":"Lancet"},{"issue":"5","key":"8_CR11","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W (2006) The follicular lymphoma international prognostic index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5):1504\u20131508","journal-title":"Blood"},{"issue":"1","key":"8_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N et al (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97(1):101\u2013106","journal-title":"Blood"},{"issue":"12","key":"8_CR13","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725\u20133732","journal-title":"Blood"},{"issue":"5","key":"8_CR14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.1991.9.5.762","volume":"9","author":"JE Romaguera","year":"1991","unstructured":"Romaguera JE, McLaughlin P, North L et al (1991) Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 9(5):762\u2013769","journal-title":"J Clin Oncol"},{"issue":"13","key":"8_CR15","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G, Mounier N, de Guibert S et al (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112(13):4824\u20134831","journal-title":"Blood"},{"issue":"9759","key":"8_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42\u201351","journal-title":"Lancet"},{"issue":"15","key":"8_CR17","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25(15):1986\u20131992","journal-title":"J Clin Oncol"},{"issue":"5","key":"8_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3816\/CLM.2006.n.024","volume":"6","author":"BS Kahl","year":"2006","unstructured":"Kahl BS (2006) Eastern Cooperative Oncology Group 4402: rituximab extended schedule or retreatment trial (RESORT). Clin Lymphoma Myeloma. 6(5):423\u2013426","journal-title":"Clin Lymphoma Myeloma."},{"issue":"5","key":"8_CR19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265","journal-title":"Blood"},{"issue":"1","key":"8_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1600-0609.2005.00564.x","volume":"76","author":"F Plancarte","year":"2006","unstructured":"Plancarte F, Lopez-Guillermo A, Arenillas L et al (2006) Follicular lymphoma in early stages: high risk of relapse and usefulness of the follicular lymphoma international prognostic index to predict the outcome of patients. Eur J Haematol 76(1):58\u201363","journal-title":"Eur J Haematol"},{"issue":"10","key":"8_CR21","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","volume":"15","author":"S Montoto","year":"2004","unstructured":"Montoto S, Lopez-Guillermo A, Altes A et al (2004) Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 15(10):1484\u20131489","journal-title":"Ann Oncol"},{"issue":"8","key":"8_CR22","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","volume":"27","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Taylor MD, Cerhan JR et al (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 27(8):1202\u20131208","journal-title":"J Clin Oncol"},{"issue":"4","key":"8_CR23","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","volume":"14","author":"MP Mac Manus","year":"1996","unstructured":"Mac Manus MP, Hoppe RT (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14(4):1282\u20131290","journal-title":"J Clin Oncol"},{"issue":"1","key":"8_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/hon.743","volume":"23","author":"RW Tsang","year":"2005","unstructured":"Tsang RW, Gospodarowicz MK (2005) Radiation therapy for localized low-grade non-Hodgkin\u2019s lymphomas. Hematol Oncol 23(1):10\u201317","journal-title":"Hematol Oncol"},{"issue":"11","key":"8_CR25","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","volume":"21","author":"JF Seymour","year":"2003","unstructured":"Seymour JF, Pro B, Fuller LM et al (2003) Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 21(11):2115\u20132122","journal-title":"J Clin Oncol"},{"issue":"8","key":"8_CR26","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ (2004) Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22(8):1454\u20131459","journal-title":"J Clin Oncol"},{"issue":"31","key":"8_CR27","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-Celigny","year":"2012","unstructured":"Solal-Celigny P, Bellei M, Marcheselli L et al (2012) Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 30(31):3848\u20133853","journal-title":"J Clin Oncol"},{"issue":"3","key":"8_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1586\/era.13.6","volume":"13","author":"ZM Li","year":"2013","unstructured":"Li ZM, Ghielmini M, Moccia AA (2013) Managing newly diagnosed follicular lymphoma: state of the art and future perspectives. Expert Rev Anticancer Ther 13(3):313\u2013325","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"8_CR29","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R et al (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104(10):3064\u20133071","journal-title":"Blood"},{"issue":"3","key":"8_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/annonc\/mdi091","volume":"16","author":"C Foussard","year":"2005","unstructured":"Foussard C, Colombat P, Maisonneuve H et al (2005) Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin\u2019s lymphoma before the era of monoclonal antibodies. Ann Oncol 16(3):466\u2013472","journal-title":"Ann Oncol"},{"issue":"10","key":"8_CR31","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, Weller E, Gascoyne RD et al (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 27(10):1607\u20131614","journal-title":"J Clin Oncol"},{"issue":"4","key":"8_CR32","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417\u20131423","journal-title":"Blood"},{"issue":"15","key":"8_CR33","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23(15):3383\u20133389","journal-title":"J Clin Oncol"},{"issue":"9873","key":"8_CR34","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210","journal-title":"Lancet"},{"issue":"19","key":"8_CR35","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944\u20132952","journal-title":"Blood"},{"issue":"1","key":"8_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mpo.2950070106","volume":"7","author":"E Baum","year":"1979","unstructured":"Baum E, Sather H, Nachman J et al (1979) Relapse rates following cessation of chemotherapy during complete remission of acute lymphocytic leukemia. Med Pediatr Oncol 7(1):25\u201334","journal-title":"Med Pediatr Oncol"},{"issue":"27","key":"8_CR37","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/JCO.2013.50.0454","volume":"31","author":"CA Jacobson","year":"2013","unstructured":"Jacobson CA, Freedman AS (2013) One size does not fit all in follicular lymphoma. J Clin Oncol 31(27):3307\u20133308","journal-title":"J Clin Oncol"},{"issue":"5","key":"8_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352(5):441\u2013449","journal-title":"N Engl J Med"},{"key":"8_CR39","doi-asserted-by":"crossref","unstructured":"Oliansky DM, Gordon LI, King J et al (2010) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 16(4):443\u2013468","DOI":"10.1016\/j.bbmt.2010.01.008"},{"key":"8_CR40","doi-asserted-by":"crossref","unstructured":"Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N (2012) High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database Syst Rev 1:CD007678","DOI":"10.1002\/14651858.CD007678.pub2"},{"issue":"6","key":"8_CR41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"BD Cheson","year":"2008","unstructured":"Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma. N Engl J Med 359(6):613\u2013626","journal-title":"N Engl J Med"},{"issue":"17","key":"8_CR42","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-Lopez AJ, White CA et al (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18(17):3135\u20133143","journal-title":"J Clin Oncol"},{"issue":"2","key":"8_CR43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L et al (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26(2):204\u2013210","journal-title":"J Clin Oncol"},{"issue":"1","key":"8_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cncr.22740","volume":"110","author":"S Sacchi","year":"2007","unstructured":"Sacchi S, Pozzi S, Marcheselli R et al (2007) Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 110(1):121\u2013128","journal-title":"Cancer"},{"issue":"11","key":"8_CR45","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/cncr.21882","volume":"106","author":"CS Tam","year":"2006","unstructured":"Tam CS, Wolf M, Prince HM et al (2006) Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 106(11):2412\u20132420","journal-title":"Cancer"},{"issue":"32","key":"8_CR46","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M et al (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(32):5165\u20135169","journal-title":"J Clin Oncol"},{"issue":"12","key":"8_CR47","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1038\/leu.2010.218","volume":"24","author":"DA Carney","year":"2010","unstructured":"Carney DA, Westerman DA, Tam CS et al (2010) Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 24(12):2056\u20132062","journal-title":"Leukemia"},{"issue":"4","key":"8_CR48","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/bmt.2011.109","volume":"47","author":"J Waterman","year":"2012","unstructured":"Waterman J, Rybicki L, Bolwell B et al (2012) Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant 47(4):488\u2013493","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"8_CR49","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.exphem.2009.07.011","volume":"37","author":"A Janikova","year":"2009","unstructured":"Janikova A, Koristek Z, Vinklarkova J et al (2009) Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients. Exp Hematol 37(11):1266\u20131273","journal-title":"Exp Hematol"},{"issue":"2","key":"8_CR50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","volume":"54","author":"F Lanza","year":"2014","unstructured":"Lanza F, Lemoli RM, Olivieri A et al (2014) Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion. 54(2):331\u2013339","journal-title":"Transfusion."},{"issue":"12","key":"8_CR51","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS et al (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99(12):4336\u20134342","journal-title":"Blood"},{"issue":"30","key":"8_CR52","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, Kaminski MS, Wahl RL et al (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas. J Clin Oncol 23(30):7565\u20137573","journal-title":"J Clin Oncol"},{"issue":"12","key":"8_CR53","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.bbmt.2013.09.004","volume":"19","author":"E Derenzini","year":"2013","unstructured":"Derenzini E, Stefoni V, Maglie R et al (2013) Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. Biol Blood Marrow Transplant 19(12):1695\u20131701","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"8_CR54","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","volume":"25","author":"MS Czuczman","year":"2007","unstructured":"Czuczman MS, Emmanouilides C, Darif M et al (2007) Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25(27):4285\u20134292","journal-title":"J Clin Oncol"},{"issue":"5","key":"8_CR55","doi-asserted-by":"publisher","first-page":"e781","DOI":"10.1016\/j.ijrobp.2010.10.013","volume":"81","author":"EK Chan","year":"2011","unstructured":"Chan EK, Fung S, Gospodarowicz M et al (2011) Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 81(5):e781\u2013786","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"8_CR56","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","volume":"98","author":"S Montoto","year":"2013","unstructured":"Montoto S, Corradini P, Dreyling M et al (2013) Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-lymphoma working party. Haematologica 98(7):1014\u20131021","journal-title":"Haematologica"},{"issue":"4","key":"8_CR57","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.bbmt.2010.01.008","volume":"16","author":"DM Oliansky","year":"2010","unstructured":"Oliansky DM, Gordon LI, King J et al (2010) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 16(4):443\u2013468","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"8_CR58","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","volume":"25","author":"AZ Rohatiner","year":"2007","unstructured":"Rohatiner AZ, Nadler L, Davies AJ et al (2007) Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 25(18):2554\u20132559","journal-title":"J Clin Oncol"},{"issue":"20","key":"8_CR59","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","volume":"119","author":"AM Evens","year":"2013","unstructured":"Evens AM, Vanderplas A, LaCasce AS et al (2013) Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 119(20):3662\u20133671","journal-title":"Cancer"},{"issue":"12","key":"8_CR60","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF, McLaughlin P, Saliba RM et al (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530\u20135536","journal-title":"Blood"},{"key":"8_CR61","doi-asserted-by":"crossref","unstructured":"Morschhauser FA, Cartron G, Thieblemont C et al (2013) Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 31(23):2912\u20132919","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"8_CR62","doi-asserted-by":"crossref","unstructured":"Radford J, Davies A, Cartron G, et al (2013) Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 122(7):1137\u20131143","DOI":"10.1182\/blood-2013-01-481341"},{"key":"8_CR63","doi-asserted-by":"crossref","unstructured":"Advani A, Coiffier B, Czuczman MS et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study. J Clin Oncol 28(12):2085\u20132093","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"8_CR64","doi-asserted-by":"crossref","unstructured":"Negrea GO, Elstrom R, Allen SL et al (2011) Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin\u2019s lymphoma. Haematologica 96(4):567\u2013573","DOI":"10.3324\/haematol.2010.037390"},{"issue":"9","key":"8_CR65","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/art.23732","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Kaine JL, Lowenstein MB et al (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58(9):2652\u20132661","journal-title":"Arthritis Rheum"},{"key":"8_CR66","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Marlton P, Vitolo U et al (2010) Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma. Ann Oncol 21(9):1870\u20131876","DOI":"10.1093\/annonc\/mdq027"},{"key":"8_CR67","doi-asserted-by":"crossref","unstructured":"Casulo C, Vose JM, Ho WY et al (2014)\u00a0A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed\/refractory CD20\u00a0+\u00a0indolent NHL: correlation between clinical responses and AUC pharmacokinetics. Clin Immunol\u00a0154(1):37\u201346","DOI":"10.1016\/j.clim.2014.06.005"},{"issue":"10","key":"8_CR68","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/cncr.23890","volume":"113","author":"JP Leonard","year":"2008","unstructured":"Leonard JP, Schuster SJ, Emmanouilides C et al (2008) Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113(10):2714\u20132723","journal-title":"Cancer"},{"key":"8_CR69","doi-asserted-by":"crossref","unstructured":"Younes A, Kim S, Romaguera J et al (2012) Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3\u00a0weeks to patients with relapsed\/refractory B-cell lymphoma. J Clin Oncol 30(22):2776\u20132782","DOI":"10.1200\/JCO.2011.39.4403"},{"key":"8_CR70","doi-asserted-by":"crossref","unstructured":"Fayad L, Offner F, Smith MR et al (2013) Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 31(5):573\u2013583","DOI":"10.1200\/JCO.2012.42.7211"},{"key":"8_CR71","doi-asserted-by":"crossref","unstructured":"Flinn IW, Kahl BS, Leonard JP et al (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123(22):3406\u20133413","DOI":"10.1182\/blood-2013-11-538546"},{"key":"8_CR72","doi-asserted-by":"crossref","unstructured":"Gopal AK, Kahl BS, de Vos S et al (2014)\u00a0PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008-1018","DOI":"10.1056\/NEJMoa1314583"},{"key":"8_CR73","doi-asserted-by":"crossref","unstructured":"Wang M, Fowler N, Wagner-Bartak N et al (2013) Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902\u20131909","DOI":"10.1038\/leu.2013.95"},{"key":"8_CR74","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Vose JM, Kelly JL et al (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117(10):2807\u20132812","DOI":"10.1182\/blood-2010-11-314708"},{"issue":"9","key":"8_CR75","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1158\/1078-0432.CCR-12-3069","volume":"19","author":"B Coiffier","year":"2013","unstructured":"Coiffier B, Li W, Henitz ED et al (2013) Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. Clin Cancer Res 19(9):2551\u20132561","journal-title":"Clin Cancer Res"},{"key":"8_CR76","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1756-8722-5-67","volume":"5","author":"PL Zinzani","year":"2012","unstructured":"Zinzani PL, Khuageva NK, Wang H et al (2012) Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol 5:67","journal-title":"J Hematol Oncol"},{"issue":"21","key":"8_CR77","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"Ramsay AG, Clear AJ, Kelly G et al (2009) Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 114(21):4713\u20134720","journal-title":"Blood"},{"key":"8_CR78","doi-asserted-by":"crossref","unstructured":"Fowler NH, Davis RE, Rawal S et al (2014) Safety and activity of lenalidomide and rituximab in untreated indolent\u00a0lymphoma: an open-label, phase 2 trial. Lancet Oncol\u00a015(12):1311\u20131318","DOI":"10.1016\/S1470-2045(14)70455-3"},{"issue":"4","key":"8_CR79","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/bjh.12915","volume":"166","author":"AM Evens","year":"2014","unstructured":"Evens AM, Smith MR, Lossos IS et al (2014) Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. Br J Haematol 166(4):514\u2013520","journal-title":"Br J Haematol"},{"issue":"32","key":"8_CR80","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig TE, Wiernik PH, Moore T et al (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 27(32):5404\u20135409","journal-title":"J Clin Oncol"},{"key":"8_CR81","doi-asserted-by":"crossref","unstructured":"Kirschbaum M, Frankel P, Popplewell L et al (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol 29(9):1198\u20131203","DOI":"10.1200\/JCO.2010.32.1398"},{"key":"8_CR82","doi-asserted-by":"crossref","unstructured":"Smith SM, van Besien K, Karrison T et al (2010) Temsirolimus has activity in non-mantle cell non-Hodgkin\u2019s lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 28(31):4740\u20134746","DOI":"10.1200\/JCO.2010.29.2813"},{"issue":"1","key":"8_CR83","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","volume":"15","author":"JR Westin","year":"2014","unstructured":"Westin JR, Chu F, Zhang M et al (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69\u201377","journal-title":"Lancet Oncol"},{"issue":"10","key":"8_CR84","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108(10):3295\u20133301","journal-title":"Blood"},{"issue":"2","key":"8_CR85","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.V97.2.404","volume":"97","author":"SJ Horning","year":"2001","unstructured":"Horning SJ, Negrin RS, Hoppe RT et al (2001) High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97(2):404\u2013409","journal-title":"Blood"},{"issue":"9","key":"8_CR86","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","volume":"104","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Schiegnitz E et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104(9):2667\u20132674","journal-title":"Blood"},{"issue":"24","key":"8_CR87","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","volume":"22","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Schiegnitz E et al (2004) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 22(24):4926\u20134933","journal-title":"J Clin Oncol"},{"issue":"8","key":"8_CR88","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"C Sebban","year":"2006","unstructured":"Sebban C, Mounier N, Brousse N et al (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). Blood 108(8):2540\u20132544","journal-title":"Blood"},{"issue":"8","key":"8_CR89","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F et al (2008) Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111(8):4004\u20134013","journal-title":"Blood"},{"issue":"5","key":"8_CR90","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","volume":"113","author":"E Gyan","year":"2009","unstructured":"Gyan E, Foussard C, Bertrand P et al (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9\u00a0years. Blood 113(5):995\u20131001","journal-title":"Blood"},{"key":"8_CR91","doi-asserted-by":"crossref","unstructured":"Federico M et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.\u00a0J Clin Oncol 27:1\u20139","DOI":"10.1200\/JCO.2008.21.3991"}],"container-title":["Cancer Treatment and Research","Non-Hodgkin Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-13150-4_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T01:42:06Z","timestamp":1717724526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-13150-4_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319131498","9783319131504"],"references-count":91,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-13150-4_8","relation":{},"ISSN":["0927-3042"],"issn-type":[{"type":"print","value":"0927-3042"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"7 February 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}